COMMUNIQUÉS West-GlobeNewswire

Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
12/02/2018
ROCKVILLE, Md., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, [...]
U.S. Patent and Trademark Office has granted to Todos Medical two additional patents
12/02/2018
REHOVOT, Israel, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Todos Medical, Ltd. Inc. (OTCQB:TOMDF) ( www.todosmedical.com ), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early [...]
Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
12/02/2018
Based on FDA Feedback, Opiant Intends to Pursue 505 (b)(2) Development Pathway Opiant Anticipates Submitting an NDA for this Product Candidate in 2020 SANTA MONICA, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Opiant [...]
India Globalization Capital’s CEO to Speak at CEO Healthcare Symposium in NY on February 12 & 13
12/02/2018
BETHESDA, Md., Feb. 12, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) announced today that Ram Mukunda will be a speaker at the upcoming CEO Healthcare Symposium in New York on February 12 [...]
Horizon Discovery Enters into License Agreement with US Immuno-Oncology Company
12/02/2018
Horizon Discovery Enters into License Agreement with US Immuno-Oncology Company Horizon out-licenses proprietary cell line and Helitron transposon gene editing technologies demonstrating Horizon's ability to generate [...]
Allergy Therapeutics: Completion of recruitment in PQ Grass Phase II trial
12/02/2018
Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Completion of recruitment in PQ Grass Phase II trial Trial running ahead of schedule with data now due in early H2 2018 12 February 2018 Allergy [...]
Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
12/02/2018
SAINT-GENIS-POUILLY, France, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ: AAAP ) (AAA or the Company), a Novartis company and leader in nuclear medicine theragnostics, today [...]
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
12/02/2018
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness will provide [...]
Akcea Therapeutics to Hold Fourth Quarter 2017 Financial Results Webcast
12/02/2018
CAMBRIDGE, Mass., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA ), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious [...]
Axovant Sciences Announces Changes to Management Team and Board of Directors
12/02/2018
Dr. David Hung resigns as CEO and continues as scientific advisor to Roivant family of companies Dr. Pavan Cheruvu appointed as CEO of Axovant Dr. Roger Jeffs, former President and co-CEO of United Therapeutics, and [...]
Evogene Financial Results for the Fourth Quarter and Full Year 2017 Earnings Announcement Schedule
12/02/2018
REHOVOT, Israel, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ: EVGN )(TASE: EVGN ), a leading biotechnology company developing novel products for life science markets through the use of a unique computational [...]
Codexis to Present at the 25th International Molecular Medicine Tri-Conference
12/02/2018
REDWOOD CITY, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS ), a leading protein engineering company, announces that John Nicols, President & CEO, will discuss the development of an improved [...]
Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond
12/02/2018
BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP ), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat [...]
ChromaDex Corporation Reports Preliminary 2017 Results
12/02/2018
IRVINE, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ: CDXC ), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, is providing [...]
ContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL™ Leveraging the 505(b)(2) Regulatory Pathway
12/02/2018
EDISON, N.J., Feb. 12, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced [...]
Genetic Technologies Limited: Update on Strategic Alliance
12/02/2018
MELBOURNE, Australia, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ: GENE ) (“Company”, “GTG”), wishes to advise that the Company is presently in discussions with the ASX regarding the [...]
Herantis Pharma strengthens team - Outi Lahdenperä and Antti Vuolanto have joined Herantis
12/02/2018
Herantis Pharma strengthens team - Outi Lahdenperä and Antti Vuolanto have joined Herantis Herantis Pharma Plc Press release 12 Feb 2018 at 9:00 am Herantis Pharma plc ("Herantis") has strengthened its core team with [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
12/02/2018
REGULATED INFORMATION GHENT, Belgium, 12 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
12/02/2018
REGULATED INFORMATION GHENT, Belgium, 12 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

Pages